Prothena Corporation PLC
PRTA6.935USD
+0.125+1.84%
取引時間 （ET）15分遅れの株価
373.29M時価総額
損失額直近12ヶ月PER
詳細情報 Prothena Corporation PLC 企業名
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
企業情報
企業コードPRTA
会社名Prothena Corporation PLC
上場日Dec 21, 2012
最高経営責任者「CEO」Dr. Gene G. Kinney, Ph.D.
従業員数163
証券種類Ordinary Share
決算期末Dec 21
本社所在地77 Sir John Rogerson's Quay, Block C
都市DUBLIN
証券取引所NASDAQ Global Select Consolidated
国Ireland
郵便番号D02 VK60
電話番号35312362500
ウェブサイトhttps://www.prothena.com/
企業コードPRTA
上場日Dec 21, 2012
最高経営責任者「CEO」Dr. Gene G. Kinney, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
--
--
Ms. Karin L. Walker, CPA
Ms. Karin L. Walker, CPA
Chief Accounting Officer
Chief Accounting Officer
--
--
Ms. Paula K. Cobb
Ms. Paula K. Cobb
Independent Director
Independent Director
--
--
Ms. Helen S. Kim
Ms. Helen S. Kim
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Mr. Richard T. Collier
Mr. Richard T. Collier
Independent Director
Independent Director
1.22K
--
Dr. Lars G. Ekman, M.D., Ph.D.
Dr. Lars G. Ekman, M.D., Ph.D.
Chairman Emeritus
Chairman Emeritus
243.00
--
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sat, Jun 7
更新時刻: Sat, Jun 7
株主統計
種類
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
14.75%
Scully (William P)
10.42%
Fennell (Todd W.)
8.53%
T. Rowe Price Associates, Inc.
6.29%
BlackRock Institutional Trust Company, N.A.
6.10%
Other
53.91%
株主統計
株主統計
比率
Fidelity Management & Research Company LLC
14.75%
Scully (William P)
10.42%
Fennell (Todd W.)
8.53%
T. Rowe Price Associates, Inc.
6.29%
BlackRock Institutional Trust Company, N.A.
6.10%
Other
53.91%
種類
株主統計
比率
Investment Advisor
41.72%
Individual Investor
18.99%
Hedge Fund
12.64%
Investment Advisor/Hedge Fund
10.92%
Venture Capital
5.48%
Research Firm
2.58%
Bank and Trust
0.65%
Pension Fund
0.21%
Sovereign Wealth Fund
0.11%
Other
6.70%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
457
50.26M
93.38%
-20.92M
2025Q1
472
64.29M
119.45%
-7.39M
2024Q4
479
65.24M
121.19%
+239.99K
2024Q3
476
59.39M
110.43%
-5.39M
2024Q2
479
58.48M
108.76%
-4.67M
2024Q1
472
60.86M
113.29%
-264.94K
2023Q4
474
56.64M
105.77%
-2.21M
2023Q3
476
55.90M
104.65%
-1.73M
2023Q2
475
55.02M
104.46%
-3.12M
2023Q1
464
54.98M
104.68%
-658.88K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Fidelity Management & Research Company LLC
7.94M
14.75%
-129.91K
-1.61%
Mar 31, 2025
Scully (William P)
5.61M
10.42%
-36.34K
-0.64%
Mar 31, 2025
Fennell (Todd W.)
4.59M
8.53%
-54.34K
-1.17%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.38M
6.29%
-232.75K
-6.43%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.29M
6.1%
-61.73K
-1.84%
Mar 31, 2025
Logos Global Management LP
2.95M
5.48%
+2.95M
--
May 29, 2025
Armistice Capital LLC
2.20M
4.08%
-40.00K
-1.79%
Mar 31, 2025
Palo Alto Investors LP
1.66M
3.08%
-78.23K
-4.50%
Mar 31, 2025
State Street Global Advisors (US)
1.52M
2.83%
-340.28K
-18.28%
Mar 31, 2025
Invus Public Equities Advisors, LLC
1.28M
2.38%
+183.72K
+16.70%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Virtus LifeSci Biotech Clinical Trials ETF
1.08%
iShares Neuroscience and Healthcare ETF
0.63%
Invesco NASDAQ Future Gen 200 ETF
0.6%
Tema Neuroscience and Mental Health ETF
0.3%
Federated Hermes MDT Small Cap Core ETF
0.3%
ALPS Medical Breakthroughs ETF
0.22%
Invesco Nasdaq Biotechnology ETF
0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
0.04%
ProShares Ultra Nasdaq Biotechnology
0.04%
iShares Biotechnology ETF
0.03%
詳細を見る
Virtus LifeSci Biotech Clinical Trials ETF
比率1.08%
iShares Neuroscience and Healthcare ETF
比率0.63%
Invesco NASDAQ Future Gen 200 ETF
比率0.6%
Tema Neuroscience and Mental Health ETF
比率0.3%
Federated Hermes MDT Small Cap Core ETF
比率0.3%
ALPS Medical Breakthroughs ETF
比率0.22%
Invesco Nasdaq Biotechnology ETF
比率0.04%
iShares ESG Aware MSCI USA Small-Cap ETF
比率0.04%
ProShares Ultra Nasdaq Biotechnology
比率0.04%
iShares Biotechnology ETF
比率0.03%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
